Shaji K. Kumar, MD

Articles

Dr. Kumar on the Evolving Role of Venetoclax in Relapsed/Refractory Multiple Myeloma

April 1st 2021

Shaji K. Kumar, MD, discusses the evolving role of venetoclax in relapsed/refractory multiple myeloma.

Dr. Kumar on the Challenges of Selecting Therapy in Heavily Pretreated Multiple Myeloma

March 12th 2021

Shaji K. Kumar, MD, discusses the challenges of selecting therapy for patients with heavily pretreated multiple myeloma.

Dr. Kumar on Treatment Selection Considerations in Multiple Myeloma

January 27th 2021

Shaji K. Kumar, MD, discusses treatment selection considerations in multiple myeloma.

Dr. Kumar on the Emergence of MRD Negativity as an End Point in Multiple Myeloma

January 20th 2021

Shaji K. Kumar, MD, discusses the emergence of minimal residual disease negativity as a surrogate end point in relapsed/refractory multiple myeloma.

Dr. Kumar on Sequencing Selinexor-Based Combinations in Multiple Myeloma

January 8th 2021

Shaji K. Kumar, MD, discusses sequencing selinexor-based combinations in relapsed/refractory multiple myeloma.

Dr. Kumar on Treatment Discontinuation in the ENDURANCE Myeloma Trial

August 4th 2020

Shaji K. Kumar, MD, discusses treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Dr. Kumar on the Rationale for the ENDURANCE Trial in Multiple Myeloma

July 17th 2020

Shaji K. Kumar, MD, discusses the rationale for conducting the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Dr. Kumar on Stem Cell Mobilization in Multiple Myeloma

June 30th 2020

Shaji K. Kumar, MD, discusses stem cell mobilization multiple myeloma.

Dr. Kumar on Takeaways From the ENDURANCE Trial in Multiple Myeloma

June 16th 2020

Shaji K. Kumar, MD, discusses key takeaways from the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Dr. Kumar on Treatment Discontinuation in the ENDURANCE Trial in Multiple Myeloma

June 3rd 2020

Shaji K. Kumar, MD, discusses the rate of treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.